Sign in
Taking people in United StatesPhase 1

PHIN-214 injections for adults with liver cirrhosis

Tests the safety of PHIN-214 injections in adults with liver cirrhosis.

Key facts

Who runs it
PharmaIN
Where
Chandler, Cleveland, Coronado, Dallas, Marrero, Philadelphia, Rochester, and San Antonio, United StatesSee the 9 sites
Trial code
Registry title
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
Status
Recruiting
Phase
Phase 1
People taking part
74 people, planned
Started
3 Jan 2022
Planned end
30 Jun 2026
Type of study
Interventional, 2 groups
Treatments tested
  • PHIN-214 Subcutaneous injection
Record updated
5 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cirrhosis (scarring of the liver) classed as Child-Pugh A or B. They will get PHIN-214 as one injection or as daily injections for 28 days.

Age
18 to 75 years
Sex
Male and female
Disease stage
Cirrhosis classed as Child-Pugh A or B (mild to moderate). It is shown by a tissue sample or by clinical, imaging or blood tests.
Earlier treatment
People with a working TIPS (a shunt placed inside the liver) cannot join. People with chronic hepatitis B can join if their treatment has been stable for at least 3 months.

Main reasons for not taking part

  • Serious lung disease, heart disease, high blood pressure or heart rhythm (EKG) problems
  • Diabetes insipidus, SIADH or other fluid or sodium balance problems, or significant kidney disease
  • In the last 3 months: brain problems from liver disease needing hospital care, bleeding from the gut or swollen veins, or type 1 hepatorenal syndrome with acute kidney injury
  • Acute-on-chronic liver failure, or acute infections including acute viral hepatitis
  • Known HIV infection; pregnancy or breastfeeding; BMI outside 18 to 40 kg/m2

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • History of cirrhosis based on histology or a combination of clinical, radiological, or biochemical assessment and classified as Child-Pugh A or B
  • Participants may be male or female aged 18 to 75 years
  • Body mass index (BMI) within the range 18 to 40 kg/m2 (inclusive) at screening
  • Female participants must be non-pregnant, non-lactating, or of non-childbearing potential or using highly efficient contraception for the full duration of the study

Who cannot take part

  • Hepatic encephalopathy (HE) or altered mental status requiring hospitalization; variceal bleeding or upper gastrointestinal bleeding; or type 1 hepatorenal syndrome with acute kidney injury (HRS-AKI) during the previous 3 months prior to Screening
  • Subjects with acute infections, including acute viral hepatitis (subjects with chronic hepatitis B are eligible if treatment regimen is stable ≥ 3 months prior to study inclusion)
  • Significant abnormalities in medical history or on physical examination, including: respiratory disease requiring therapy or history of respiratory failure, cardiovascular disease or hypertension, electrocardiogram abnormalities or history of significant EKG abnormalities
  • Significant kidney disease
  • Acute-on-chronic liver failure
  • Known positive HIV serology confirmed by HIV viral load
  • History of diabetes insipidus, syndrome of inappropriate antidiuretic hormone secretion, or any other disorder associated with fluid or sodium imbalance
  • Recipient of a patent transjugular intrahepatic portosystemic shunt (TIPS)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Arizona Liver HealthChandler, United StatesContact: Angie Coste, FNP-CTaking people
  • Cleveland ClinicCleveland, United StatesContact: Keralee MoreyTaking people
  • Southern California Research CenterCoronado, United StatesContact: Kasey SeyerTaking people
  • Methodist Health System, Dallas Medical CenterDallas, United StatesContact: Crystee CooperTaking people
  • VA North Texas Healthcare SystemDallas, United StatesContact: Jacqueline O'Leary, MDTaking people
  • Tandem Clinical ResearchMarrero, United StatesContact: Alexis JohnsonTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Margaret BussineauTaking people
  • Mayo ClinicRochester, United StatesContact: Amy Olofson, RNTaking people
  • Texas Liver InstituteSan Antonio, United StatesContact: Eric Lawitz, MDTaking people

About the trial

What the trial wants to find out

This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.

The 2 groups in the trial

  • single dose of PHIN-214Treatment being tested

    Participants in Part 1 will receive one dose of PHIN-214 administered subcutaneously. Dose level will be assigned in ascending doses to observe initial safety and tolerability. A Safety Committee will review information from each patient and determine the dose level for the subsequent participants.

    Treatment: PHIN-214 Subcutaneous injection

  • multiple daily dosing of PHIN-214Treatment being tested

    Participants in Part 2 will be trained to give themselves a daily dose of PHIN-214 at home by subcutaneous injection for 28-days. The dose level assigned to each participant will be determined by a Safety Committee after reviewing information from the last participants' experience and compilation of experiences on all previous participants. Dose level advancement will be guided throughout the study by the experiences and information collected from each participant.

    Treatment: PHIN-214 Subcutaneous injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults With Child Pugh A and B Cirrhosis
Plain-language title
PHIN-214 injections for adults with liver cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05490888, who can take part
Record updated
5 September 2025